Patients Make New Medicines Possible

Pieris Pharmaceuticals is currently enrolling patients in respiratory and immuno-oncology clinical trials. New treatments are made possible by volunteers who participate in clinical trials and we highly encourage and welcome your participation.

Respiratory Trials

A Phase 2 Dose-escalating Trial of Elarekibep (PRS-060/AZD1402) for Asthma

Our Phase 2 study is designed to investigate the safety, tolerability, pharmacokinetics, and efficacy of multiple doses of elarekibep, a promising drug candidate being developed to treat asthma. Elarekibep will be administered by oral inhalation to subjects with moderate asthma.

About Elarekibep (PRS-060/AZD1402) Dose-escalating Clinical Trial
A Phase 1 Healthy Volunteer Trial of PRS-220 for IPF

Our Phase 1 study is designed to investigate the safety, tolerability, and pharmacokinetics of PRS-220, a drug candidate being developed to treat IPF.

About Phase 1 Healthy Volunteer Trial of PRS-220

Immuno-Oncology Trials

A Phase 1 Study of PRS-344/S095012 to Treat Advanced Solid Tumors

This global, open-label phase 1/2 dose escalation study is evaluating the safety, tolerability, potential optimal dosage, and potential anti-tumor activity of PRS-344/S095012 in patients with advanced solid tumors whose cancer progressed on standard-of-care treatment.